Gerhard Hannig - Concepedia

Author

Gerhard Hannig

Ironwood Pharmaceuticals (United States)

Also Known As

G Hannig, G. Hannig, GERHARD HANNIG, Gerhard Hannig, Hannig, G., Inmaculada Silos-Santiago

Publications

2.6K

Citations

H-Index

Concepts

All Affiliations

Ironwood Pharmaceuticals (United States)Harvard University Tris Pharma (United States)University of Oklahoma Health Sciences Center Flinders University

About

Gerhard Hannig is an author at Ironwood Pharmaceuticals (United States) specializing in medicine, natural sciences, and molecular biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	14	840
2	Natural Sciences	9	9	468
3	Biochemistry	5	5	514
4	Cell Biology	5	5	140
5	Health Sciences	2	2	55

Gerhard Hannig

Publications

2.4K

Citations

H-Index

Page 1

	Year	Citations
Strategies for optimizing heterologous protein expression in Escherichia coli Gerhard Hannig, Savvas C. Makrides Trends in biotechnology Protein ExpressionMolecular BiologyEscherichia ColiProtein SynthesisProtein Biosynthesis	1998	485
Linaclotide Inhibits Colonic Nociceptors and Relieves Abdominal Pain via Guanylate Cyclase-C and Extracellular Cyclic Guanosine 3′,5′-Monophosphate Joel Castro, Andrea M. Harrington, Patrick A. Hughes, Gastroenterology	2013	285
Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit Robert Busby, Alexander P. Bryant, Wilmin Bartolini, European Journal of Pharmacology Signal TransductionBiochemistryEnhanced Intestinal SecretionNatural SciencesGastroenterology	2010	245
Linaclotide is a potent and selective guanylate cyclase C agonist that elicits pharmacological effects locally in the gastrointestinal tract Alexander P. Bryant, Robert Busby, Wilmin Bartolini, Life Sciences Molecular PharmacologyBiochemistryGastrointestinal PharmacologyMedicineGastroenterology	2010	221
Pharmacologic Properties, Metabolism, and Disposition of Linaclotide, a Novel Therapeutic Peptide Approved for the Treatment of Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation Robert Busby, Marco M. Kessler, Wilmin Bartolini, Journal of Pharmacology and Experimental Therapeutics	2012	132
A methionine aminopeptidase-2 inhibitor, PPI-2458, for the treatment of rheumatoid arthritis Sylvie G. Bernier, Douglas Lazarus, Edward J. Clark, Proceedings of the National Academy of Sciences	2004	108
Chronic linaclotide treatment reduces colitis-induced neuroplasticity and reverses persistent bladder dysfunction Luke Grundy, Andrea M. Harrington, Joel Castro, JCI Insight Pain MedicineImmunologyGastroenterologyPathologyNeuropathic Pain	2018	80
Methionine aminopeptidases type I and type II are essential to control cell proliferation Sylvie G. Bernier, Nazbeh Taghizadeh, Charles D. Thompson, Journal of Cellular Biochemistry	2005	72
Gastrointestinal pain: Unraveling a novel endogenous pathway through uroguanylin/guanylate cyclase-C/cGMP activation Inmaculada Silos‐Santiago, Gerhard Hannig, Hélène Eutamène, Pain	2013	69
Recombinant Glycoproteins That Inhibit Complement Activation and Also Bind the Selectin Adhesion Molecules Charles W. Rittershaus, Lawrence J. Thomas, David P. Miller, Journal of Biological Chemistry	1999	56

Page 1